Latest News About Combigan Eye Drop

Updated 2026-04-20 10:04

I don’t have live access to current news feeds in this moment. Here’s what I can share based on reliable, historical context and public information up to now, and I can fetch current updates if you’d like me to search again.

If you want, I can perform a fresh web search for the latest news on Combigan and summarize the top developments (FDA/other regulator actions, new study results, safety advisories, or formulation/brand changes) with direct citations. Would you like me to fetch current updates now?

Sources

Allergan, Inc. Receives FDA Approval For COMBIGAN(TM ...

Allergan, Inc. (NYSE:AGN) today announced that the U.S. Food and Drug Administration has approved COMBIGAN(TM) (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%, an alpha adrenergic receptor agonist with a beta adrenergic receptor inhibitor, for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP. COMBIGAN(TM) is the newest addition to Allergan's...

www.ophthalmologyweb.com

FDA approves combo eye drop for glaucoma

Regulators approved a new glaucoma treatment -- Combigan, an eye drop that treats the potentially blinding eye condition with two drugs that work through different mechanisms, Allergan Inc said Wednesday.

www.reuters.com

Allergan, Inc. Receives FDA Approval For COMBIGAN ...

Allergan, Inc. (NYSE:AGN) announced that the U.S. Food and Drug Administration has approved COMBIGAN™ (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%, an alpha adrenergic receptor agonist with a beta adrenergic receptor inhibitor, for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP. COMBIGAN™ is the newest addition to Allergan's...

www.ophthalmologyweb.com